Japan approves first commercial stem cell treatments for Parkinson's and heart failure

sciencealert.com

Japan has approved the world's first commercial stem cell treatments for Parkinson's disease and severe heart failure. Sumitomo Pharma's Parkinson's treatment, Amchepry, transplants stem cells into the brain, while Cuorips' ReHeart uses heart muscle sheets to restore function. These therapies, utilizing induced pluripotent stem cells (iPS cells), could be available to patients as early as summer 2026.


With a significance score of 5.6, this news ranks in the top 0.7% of today's 33080 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: